{"id":"tetracycline-metronidazole-bismuth-subcitrate","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Metallic taste (metronidazole)"},{"rate":"1-3","effect":"Photosensitivity (tetracycline)"},{"rate":"common","effect":"Black stool discoloration (bismuth)"}]},"_chembl":null,"_dailymed":{"setId":"c50626a2-5969-490b-a88a-a4ee45e79615","title":"PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE) CAPSULE [H2-PHARMA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Metronidazole generates reactive oxygen species that damage bacterial DNA. Bismuth subcitrate disrupts the bacterial cell wall and enhances the bactericidal activity of the other agents. Together, they form a potent triple therapy regimen for H. pylori eradication.","oneSentence":"This triple-drug combination eradicates Helicobacter pylori by combining tetracycline's protein synthesis inhibition, metronidazole's DNA damage, and bismuth's bacterial cell wall disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:37.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection and associated peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT06943794","phase":"NA","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Gastric (Stomach) Cancer","enrollment":4824},{"nctId":"NCT07010744","phase":"NA","title":"Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Akil Al Islam","startDate":"2025-07-01","conditions":"Dyspepsia","enrollment":66},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT07144657","phase":"PHASE2","title":"Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-01","conditions":"MALT Lymphoma of Stomach","enrollment":40},{"nctId":"NCT06687473","phase":"PHASE4","title":"Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-01-01","conditions":"Helicobacter Pylori, Drug Resistance, Multiple, Virulence Factor","enrollment":13},{"nctId":"NCT06687499","phase":"PHASE4","title":"14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-08-22","conditions":"Helicobacter Pylori, Drug Resistance, Multiple","enrollment":46},{"nctId":"NCT06509139","phase":"PHASE4","title":"Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-07-09","conditions":"Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy","enrollment":661},{"nctId":"NCT04527055","phase":"PHASE4","title":"The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Dysbiosis, Probiotics","enrollment":312},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT04853875","phase":"PHASE4","title":"ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2021-04-19","conditions":"Helicobacter Pylori Infection","enrollment":104},{"nctId":"NCT05002595","phase":"","title":"H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2018-01-01","conditions":"H. Pylori Infection","enrollment":270},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT02490839","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT04066257","phase":"PHASE1","title":"Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-01-17","conditions":"Healthy","enrollment":32},{"nctId":"NCT02547038","phase":"NA","title":"Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2015-02","conditions":"Helicobacter Pylori Infection","enrollment":352},{"nctId":"NCT03925818","phase":"NA","title":"Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication","status":"TERMINATED","sponsor":"Università degli Studi di Sassari","startDate":"2017-08-29","conditions":"Helicobacter Pylori Infection","enrollment":99},{"nctId":"NCT02483715","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":589},{"nctId":"NCT02894268","phase":"PHASE4","title":"Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2016-02","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT02541864","phase":"NA","title":"Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2013-07","conditions":"Helicobacter Pylori Infection","enrollment":330},{"nctId":"NCT01906879","phase":"PHASE4","title":"Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-06","conditions":"Helicobacter Pylori Infection","enrollment":1620},{"nctId":"NCT03146325","phase":"PHASE4","title":"Helicobacter Pylori and Body Iron in Adults","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2012-11","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT00669955","phase":"PHASE3","title":"Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-06","conditions":"Helicobacter Infections","enrollment":440},{"nctId":"NCT00712413","phase":"PHASE3","title":"Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori","status":"WITHDRAWN","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT02682446","phase":"","title":"The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2007-01","conditions":"Gastric Cancer","enrollment":800},{"nctId":"NCT01306786","phase":"NA","title":"Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":800},{"nctId":"NCT01760824","phase":"NA","title":"Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2011-05","conditions":"Helicobacter Pylori Infection","enrollment":391},{"nctId":"NCT00003151","phase":"PHASE2","title":"Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-09","conditions":"Lymphoma","enrollment":96},{"nctId":"NCT01335334","phase":"PHASE4","title":"H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study","status":"UNKNOWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-03","conditions":"H. Pylori Infection","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":168,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bismuth Trioxide"],"phase":"marketed","status":"active","brandName":"Tetracycline, Metronidazole, Bismuth subcitrate","genericName":"Tetracycline, Metronidazole, Bismuth subcitrate","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-drug combination eradicates Helicobacter pylori by combining tetracycline's protein synthesis inhibition, metronidazole's DNA damage, and bismuth's bacterial cell wall disruption. Used for Helicobacter pylori infection and associated peptic ulcer disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}